Thrivent Financial for Lutherans Has $48.68 Million Stake in Progyny, Inc. $PGNY

Thrivent Financial for Lutherans decreased its position in Progyny, Inc. (NASDAQ:PGNY) by 12.2% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,895,605 shares of the company’s stock after selling 262,705 shares during the period. Thrivent Financial for Lutherans’ holdings in Progyny were worth $48,679,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Progyny by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 10,106,147 shares of the company’s stock worth $217,484,000 after purchasing an additional 235,513 shares during the period. Ameriprise Financial Inc. boosted its stake in Progyny by 37.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock worth $43,933,000 after purchasing an additional 545,431 shares during the period. ArrowMark Colorado Holdings LLC boosted its stake in Progyny by 2.1% in the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,931,249 shares of the company’s stock worth $41,560,000 after purchasing an additional 39,666 shares during the period. Fort Washington Investment Advisors Inc. OH boosted its stake in Progyny by 10.7% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,834,104 shares of the company’s stock worth $47,100,000 after purchasing an additional 177,546 shares during the period. Finally, Barclays PLC boosted its stake in Progyny by 79.2% in the 3rd quarter. Barclays PLC now owns 1,575,470 shares of the company’s stock worth $33,904,000 after purchasing an additional 696,447 shares during the period. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Stock Up 1.7%

Shares of NASDAQ:PGNY opened at $23.25 on Friday. The firm has a fifty day moving average of $18.38 and a two-hundred day moving average of $21.83. The firm has a market capitalization of $1.82 billion, a P/E ratio of 30.19, a price-to-earnings-growth ratio of 1.24 and a beta of 0.91. Progyny, Inc. has a 12-month low of $16.10 and a 12-month high of $28.75.

Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, May 7th. The company reported $0.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.26 by $0.03. The company had revenue of $328.50 million during the quarter, compared to analyst estimates of $326.47 million. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The company’s revenue for the quarter was down 26.4% on a year-over-year basis. During the same quarter last year, the business posted $0.17 EPS. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Equities research analysts expect that Progyny, Inc. will post 1.12 earnings per share for the current fiscal year.

Insider Activity

In related news, EVP Allison Swartz sold 4,657 shares of Progyny stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $17.40, for a total value of $81,031.80. Following the completion of the sale, the executive vice president owned 89,879 shares of the company’s stock, valued at approximately $1,563,894.60. The trade was a 4.93% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders have sold 7,455 shares of company stock valued at $129,515. 9.90% of the stock is currently owned by insiders.

Analyst Ratings Changes

PGNY has been the subject of a number of recent analyst reports. Zacks Research raised shares of Progyny from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Citizens Jmp lifted their target price on shares of Progyny from $30.00 to $31.00 and gave the company a “market outperform” rating in a research note on Monday, May 11th. Wall Street Zen raised shares of Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, April 18th. JPMorgan Chase & Co. set a $35.00 target price on shares of Progyny in a research note on Wednesday, January 21st. Finally, Citigroup reissued an “outperform” rating on shares of Progyny in a research note on Monday, May 11th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, Progyny presently has a consensus rating of “Moderate Buy” and an average price target of $28.55.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.